Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its patented first-in-class drug candidate, Lucid-MS, toward Phase 2 clinical trials for the treatment of multiple sclerosis (MS). The company recently filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration, following successful completion of Phase 1 safety studies and key toxicology programs. Unlike existing MS therapies that primarily target the immune system, Lucid-MS is a nonimmunomodulatory, neuroprotective compound designed to directly protect the myelin sheath, which is damaged in MS.
The development is based on more than a decade of preclinical research, including studies in animal models that demonstrated preservation of myelin integrity, reduced degradation, and improved functional recovery. The company is also collaborating with Massachusetts General Hospital on a novel PET imaging technique aimed at directly measuring myelin integrity in MS patients, a tool that could help evaluate the effectiveness of remyelinating therapies.
Recent clinical and regulatory developments from other major pharmaceutical companies, including Novartis AG (NYSE: NVS), Merck & Co. Inc. (NYSE: MRK), TG Therapeutics Inc. (NASDAQ: TGTX), and Bristol Myers Squibb Company (NYSE: BMY), underscore continued innovation across autoimmune, immune-mediated, and chronic inflammatory disease treatment markets. Quantum BioPharma's progress with Lucid-MS represents a potential paradigm shift in MS treatment, offering a mechanism that directly addresses the underlying pathology rather than modulating the immune system.
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets for the treatment of neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company focuses on the research and development of Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
For more information, see the full press release at https://ibn.fm/6ylQf.
